Description: Mesoblast Limited is engaged in developing cell-based medicines. The Company has leveraged its technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a portfolio of late-stage product candidates. Its allogeneic, off-the-shelf cell product candidates target advanced stages of diseases with high, unmet medical needs, including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions.
Home Page: www.mesoblast.com
MSB Technical Analysis
Massmutual Select Funds
,
Phone:
61 3 9639 6036
Officers
| Name | Title |
|---|---|
| Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons) | Founder, CEO, MD, Chairman of Scientific Advisory Board & Exec. Director |
| Dr. Eric A. Rose M.D. | Chief Medical Officer & Exec. Director |
| Mr. Andrew Chaponnel B.Com. | Interim Chief Fin. Officer |
| Ms. Dagmar Rosa-Bjorkeson M.B.A., M.S. | Chief Operating Officer |
| Mr. Peter T. Howard B.Sc., L.L.B., BSc, LLB (Hons) | Gen. Counsel & Corp. Exec. |
| Mr. Roger D. Brown BA | Head of Spinal Orthopedic Disorders |
| Mr. Michael Schuster M.B.A., MS, BSc, MBA | Head of Pharma Partnering |
| Ms. Geraldine Storton B.Sc., M.B.A., Bsc, MMS, MBA | Head of Regulatory Affairs & Quality Management |
| Mr. Justin Horst B.S. | Head of Manufacturing |
| Ms. Niva Sivakumar B.Com., L.L.B. | Joint Company Sec. |
Exchange: AU
Country: AU
Currency: Australian Dollar (A$)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 769.2308 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.8277 |
| Price-to-Sales TTM: | 86.176 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 77 |